{
  "chapter": "Hematology-Multiple Myeloma",
  "questions": [
    {
      "q_no": 1,
      "question": "A 70-year-old woman presents to the emergency department with severe back pain and weakness in her legs. She has been experiencing fatigue and increased thirst for the past month. Laboratory tests reveal: Serum calcium : 13 mg/dL Serum creatinine : 150 µ mol/L (1.7 mg/dL) Hemoglobin : 8.5 g/dL Alkaline phosphatase (ALP) : 70 U/L (normal range) Serum phosphate : 3.5 mg/dL (normal) Imaging reveals findings as shown: Based on this clinical presentation, what is the most likely diagnosis?",
      "options": {
        "A": "Osteoporosis",
        "B": "Paget’s disease of bone",
        "C": "Multiple Myeloma",
        "D": "Renal osteodystrophy"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Multiple Myeloma Explanation: The combination of hypercalcemia , renal insufficiency , and anemia , along with the presence of vertebral fractures, indicates multiple myeloma . The disease is characterized by malignant plasma cells leading to osteolytic bone lesions, which can result in fractures, hypercalcemia, and renal damage. Diagnostic Criteria for Multiple Myeloma (Option C) Presence of clonal bone",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Hematology-Multiple_Myeloma_Q1_q.png",
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 2,
      "question": "A 58-year-old male presents with fatigue, bone pain, and an elevated serum protein level. Bone marrow biopsy reveals 40% plasma cells. Cytogenetic studies show the following abnormalities: t(4;14), del 17p, and gain of 1q. Based on the mSMART 3.0 classification, which of the following best describes the patient’s risk stratification?",
      "options": {
        "A": "Standard-risk myeloma",
        "B": "Double-hit myeloma",
        "C": "High-risk myeloma",
        "D": "Triple-hit myeloma"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Triple-hit myeloma Explanation: The patient has three high-risk genetic abnormalities (t(4;14), del 17p, & gain of 1q), which places him in the category of \"triple-hit\" myeloma according to the mSMART 3.0 classification. Etiology : Higher incidence is observed in those exposed to radiation and among farmers , woodworkers , and those exposed to petroleum products . Hyperdiploidy ( trisomies of chromosomes 3, 5, 7 ) Translocations involving chromosome 14 (e.g., t(11;14), t(4;14), t(14;16)). Deletion of 13q14 , 17p13 and amplification of 1q . Common mutations include N-ras, K-ras, and B-raf, but no single genetic pathway dominates. Myeloma evolves with subclonal mutations over time, driving disease progression, and interleukin-6 (IL-6) may promote myeloma cell growth. mSMART 3.0: Classification of Active MM High-Risk (Option C) Standard-Risk (Option A) High-risk genetic Abnormalities: t(4;14) t(14;16) t(14;20) Del 17p p53 mutation Gain 1q RISS Stage 3 High Plasma Cell S-phase GEP: High-risk signature All others, including: Trisomies t(11;14) t(6;14) Double Hit Myeloma : Any 2 high-risk genetic abnormalities. (Option B) Triple Hit Myeloma : 3 or more high-risk genetic abnormalities. (Option D) Reference: Harrison’s Principles of Internal Medicine 21st edition Page 868 https://globalmmacademy.com/wp-content/uploads/2021/03/RiskStrat3.0rev_svr_Mayo-clinic.pdf",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 3,
      "question": "In multiple myeloma, osteoblast suppression is primarily associated with which of the following factors?",
      "options": {
        "A": "Increased expression of RANKL by osteoblasts.",
        "B": "Enhanced production of macrophage inflammatory protein-1 alpha (MIP-1alpha).",
        "C": "Elevated levels of Dickkopf 1 (DKK1) blocking Wnt signaling.",
        "D": "Decreased levels of IL-3 and IL-7."
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Elevated levels of Dickkopf 1 (DKK1) blocking Wnt signaling. Explanation: Multiple myeloma cells secrete DKK1 , leading to the suppression of osteoblast activity and promoting osteolytic lesions . By blocking Wnt signaling, DKK1 inhibits the normal process of bone formation, contributing to the imbalance between osteoclast and osteoblast activity in MM. Pathophysiology of Multiple myeloma: The pathogenesis of multiple myeloma (MM) can be viewed as a two-step sequential process. Cytogenetic Abnormalities: Translocations involving the immunoglobulin heavy chain (IgH) locus. Genetic instability, represented by trisomies . A combination of translocations and trisomies. Key genetic drivers of progression include: MYC activation (via structural rearrangements) TP53 deletion (by 17p deletion or mutations) RAS/MAPK pathway activation (NRAS, KRAS, BRAF mutations) NF κ B pathway activation (mutations in TRAF3, CYLD, NIK) Apoptosis dysregulation (MCL1 overexpression) Bone Marrow Microenvironment Composed of mesenchymal stem cells, osteoclasts, immune cells, an extracellular matrix, and soluble factors. Changes in the microenvironment promote plasma cell survival and MGUS to MM progression, including: Induction of angiogenesis. Immune dysregulation. Paracrine loops involving cytokines like IL-6 and VEGF. Modulation of tumor growth by stromal cells. Pathobiology of End-Organ Damage Osteolytic bone lesions : These lesions are caused by an imbalance between osteoclast (bone resorption) and osteoblast (bone formation) activity, with increased osteoclastic activity and suppressed osteoblastic function in MM. Increased osteoclast activity This is driven by elevated RANKL expression (Option A ruled out) from osteoblasts and possibly plasma cells, along with reduced levels of its decoy receptor, osteoprotegerin (OPG) . This imbalance (high RANKL/OPG ratio) promotes osteoclast activation and bone resorption. Additionally, macrophage inflammatory protein-1 alpha (MIP-1alpha) (Option B ruled out) , IL-3, IL-6, and stromal-derived factor 1 alpha (SDF-1alpha) contribute to osteoclast overactivity. Osteoblast suppression Suppression is linked to increased levels of IL-3, IL-7, and Dickkopf 1 (DKK1), which inhibits osteoblast differentiation. DKK1, secreted by MM cells, blocks Wnt signaling and is associated with the presence of bone lesions. (Option C) Elevated levels of IL-3 and IL-7 further inhibit osteoblast function. (Option D ruled out) Kidney impairment : Primarily results from monoclonal immunoglobulin light chains, with occasional involvement of heavy chains or whole immunoglobulins. Anemia : Results from tumour replacement of normal hematopoietic tissue (myelophthisis) and disruption of the bone marrow microenvironment, leading to a reduction in hematopoietic stem and progenitor cells.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 4,
      "question": "A 65-year-old male presents with severe back pain, fatigue, confusion, and lethargy. Imaging reveals multiple osteolytic lesions; lab tests show elevated calcium and anemia, and serum protein electrophoresis identifies a monoclonal spike. Given this presentation, which complication is most likely contributing to his neurologic symptoms?",
      "options": {
        "A": "Spinal cord compression from vertebral collapse",
        "B": "Hyperviscosity syndrome from increased serum proteins",
        "C": "Hypercalcemia from bone destruction",
        "D": "Peripheral neuropathy due to plasma cell infiltration"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Hypercalcemia from bone destruction Explanation: The patient has multiple myeloma , leading to bone destruction and elevated calcium levels. Given the patient's symptoms of severe back pain, osteolytic lesions, and lab findings of hypercalcemia are the most likely cause of his neurological symptoms like confusion and lethargy . Clinical manifestations of Multiple Myeloma : Bone manifestation Bone pain is the most common symptom , affecting ~70% of patients. Persistent pain often indicates a pathologic fracture. Caused by tumour cell proliferation, osteoclast activation, and osteoblast suppression. Osteoclast activation is driven by cytokines like IL-1, VEGF, RANK ligand, and TNF, leading to bone destruction and lytic lesions. Osteoblast suppression is mediated by DKK-1, resulting in minimal new bone formation. Hypercalcemia : Results from bone destruction, causing both acute and chronic complications. Vertebral collapse may lead to spinal cord compression. Infections 2nd most common clinical issue Frequent pathogens include S. pneumoniae, S. aureus, and K. pneumoniae in the lungs, and E. coli in the urinary tract. Immune dysfunction is caused by hypogammaglobulinemia , abnormal T-cell function (reduced TH1, increased TH17), and impaired complement activity. Renal Manifestation Common causes include hypercalcemia (most common), amyloid deposits, hyperuricemia, infections, NSAIDs, iodinated contrast, bisphosphonates, and myeloma cell infiltration. Light Chain Damage : Excessive light chains in tubules cause damage, leading to adult Fanconi's syndrome (proximal renal tubular acidosis) with loss of glucose, amino acids, and impaired kidney function. Proteinuria : Mainly light chain proteinuria, minimal albumin unless glomeruli are involved. Decreased anion gap due to cationic M component causing chloride retention. Pseudohyponatremia may occur due to reduced serum water content from increased proteins (Increased proteins retain water, leading to falsely low sodium levels) Patients are susceptible to renal failure, especially if dehydrated. Anemia : Normocytic, normochromic anaemia occurs in ~80% of patients due to marrow replacement, reduced erythropoietin production, and therapy effects. Some may develop megaloblastic anaemia due to folate or B12 deficiency. Clotting Abnormalities : Dysfunctional antibody-coated platelets and interactions between the M component and clotting factors can lead to clotting issues. Hyperviscosity Syndrome : Caused by high paraprotein concentrations (especially IgM, IgG3, IgA), leading to increased serum viscosity. Symptoms include headache, visual disturbances, fatigue, and coma. (Option B) Neurologic Symptoms : Causes include hypercalcemia (lethargy, confusion) (Option C) , hyperviscosity (ataxia, coma), and bony damage (cord compression, radicular pain). Peripheral nerve infiltration by amyloid can cause neuropathy. (Option D) Tumor Expansion : Although plasma cells spread widely, tumour expansion predominantly occurs within bone and bone marrow, with minimal involvement of lymph nodes, spleen, or gut-associated lymph tissue. Spinal cord",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 5,
      "question": "A 68-year-old woman presents to the clinic with increasing fatigue and bone pain. Laboratory tests reveal normocytic anemia, a high serum calcium level, and a serum protein electrophoresis that shows a significant monoclonal spike. Which cytokine is likely contributing to her anemia by inhibiting iron release?",
      "options": {
        "A": "Interleukin-1 (IL-1)",
        "B": "Interleukin-6 (IL-6)",
        "C": "Interleukin-5 (IL-5)",
        "D": "Vascular endothelial growth factor (VEGF)"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Interleukin-6 (IL-6) Explanation: IL-6 is produced by both myeloma cells and the bone marrow stroma and plays a significant role in the anemia of multiple myeloma by increasing hepcidin levels, which inhibit iron release from macrophages and reduce intestinal iron absorption. Hematologic Abnormalities in Myeloma Anemia : Normocytic and normochromic anemia affects ~80% of myeloma patients. Caused by: Replacement of normal marrow by tumor cells. Tumor-induced inhibition of hematopoiesis. Reduced erythropoietin production from the kidneys. Long-term therapy effects. IL-6 Overproduction : Produced by marrow stroma and myeloma cells, contributing to anemia by increasing hepcidin levels, which inhibits iron release from macrophages and reduces intestinal iron absorption. Clotting Abnormalities : Result from dysfunctional antibody-coated platelets or interactions with clotting factors. Amyloid damage to endothelial cells may contribute. Hypercoagulable States : Result from defective fibrin structure and fibrinolysis due to elevated immunoglobulin levels, acquired protein C resistance, and increased proinflammatory cytokines. Bleeding Complications : Generally uncommon but more frequent with IgA paraproteins, high serum immunoglobulin levels, and increased serum viscosity. Acquired von Willebrand factor deficiency may occur. Raynaud’s phenomenon and impaired circulation can occur if the M component forms cryoglobulins. Thrombocytopenia : Rare in the early stages of myeloma, even with significant marrow involvement. Thrombocytosis : May indicate hyposplenism due to amyloid deposition in the spleen. Lupus anticoagulants : Have been observed in some myeloma patients. IL-1 (Option A) is an inflammatory cytokine involved in the immune response. IL-5 (Option C) primarily plays a role in the growth and differentiation of eosinophils VEGF (Option D) is mainly associated with angiogenesis and vascular permeability. Reference: Harrison’s Principles of Internal Medicine, 21st edition, Page 870 Williams Manual of Hematology, 10th edition, Page 487",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 6,
      "question": "A 68-year-old male presents with fatigue, bone pain, anemia, hypercalcemia, and elevated creatinine. Imaging reveals multiple lytic bone lesions, and serum electrophoresis shows an M spike. Bone marrow biopsy reveals 15% clonal plasma cells. What is the most likely diagnosis?",
      "options": {
        "A": "Multiple myeloma",
        "B": "Solitary plasmacytoma",
        "C": "Smouldering multiple myeloma",
        "D": "Monoclonal Gammopathy of Undetermined Significance"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Multiple myeloma Explanation: Clinical features of CRAB (hypercalcemia, renal dysfunction, anemia, and bone lesions), along with lytic bone lesions, the presence of an M spike in serum electrophoresis, and >10% clonal plasma cells in the bone marrow, point towards the diagnosis of Multiple myeloma. Investigations of Multiple myeloma: Hematological Analysis: It may reveal anemia; ESR is usually elevated. Rare cases of plasma cell leukemia with high plasma cell counts >2000 plasma cells/ µ L. Serum calcium and urea nitrogen may be elevated. Serum alkaline phosphatase is usually normal. Peripheral smear: Rouleaux formation A/G ratio: Decreased Increased level of β 2 microglobulin. Decreased albumin Renal function test: Increased serum creatinine and uric acid. Imaging: Chest and bone radiographs: Lytic lesions/diffuse osteopenia MRI: Extent of bone marrow infiltration and cord or root compression in patients with pain syndrome PET/CT: Assess bone damage, extramedullary sites of the disease Anion gap: (Na+ + K+) – (Cl- + HCO3-): Decreased Serum or urine electrophoresis: M spike Serum light chain assay: Increased Immunofixation: Detects subtypes of light chain. 24-hour urine specimen: Bence Jones protein (serum-free light chains) excretion Fat pad biopsy: To detect amyloid deposits Flow cytometry: CD 138+ (bone marrow plasma cells) FISH: Done to detect chromosomal abnormalities Chromosome 17 deletion and translocation leads to poor prognosis. Bone marrow biopsy: Plasmacytosis >10% Clinicopathologic diagnosis of multiple myeloma is based on the following: Clonal plasma cells in bone marrow Presence of CRAB criteria (hypercalcemia, renal dysfunction, anemia and bone lesions) Solitary plasmacytoma (Option B) is characterized by a biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells, normal bone marrow, and the absence of end-organ damage (CRAB features), making it unlikely in this patient. Smouldering multiple myeloma (Option C) is not applicable because, although the patient has >10% clonal plasma cells, they also present with significant clinical symptoms and myeloma-defining events, including CRAB features (hypercalcemia, renal dysfunction, and lytic bone lesions), which are inconsistent with the asymptomatic nature of smouldering multiple myeloma. Monoclonal Gammopathy of Undetermined Significance (Option D) (MGUS) is unlikely because it involves serum monoclonal protein <30 g/L, clonal plasma cells <10%, and the absence of CRAB features (hypercalcemia, renal dysfunction, anemia, or bone lesions), all of which are present in this case. Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page 871,872 Davidson’s Principles and Practice of Medicine, 24th Edition, Page 967 Robbins & Cotran Pathologic Basis of Disease, 10th Edition, Page 609 https://pmc.ncbi.nlm.nih.gov/articles/PMC6650180/ https://journals.lww.com/jasn/fulltext/2022/11001/hyperuricemia_and_kidney_function_in_patients.2257.aspx https://pmc.ncbi.nlm.nih.gov/articles/PMC4973001/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 7,
      "question": "A 65-year-old male presents with fatigue, bone pain, and recurrent infections. Laboratory tests show anemia, elevated serum creatinine, and hypercalcemia. An X-ray of the skull reveals findings as shown in the image. Which of the following findings is not consistent with a diagnosis in this patient?",
      "options": {
        "A": "Biopsy shows increased plasma cells in the bone marrow >30% cellularity.",
        "B": "Immunofixation identifies heavy or light chain isotypes of abnormal proteins.",
        "C": "Biopsy shows the presence of Russell and Dutcher bodies in the bone marrow.",
        "D": "Serum electrophoresis reveals a broad, plateau-like peak in the beta region."
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Serum electrophoresis reveals a broad, plateau-like peak in the beta region. recurrent infections, anemia, elevated serum creatinine, hypercalcemia, and the \"raindrop\" appearance of the skull due to osteolytic lesions . Patients with multiple myeloma typically show a sharp, spire-like peak in the gamma region , not a broad plateau in the beta region. Bone Marrow Biopsy Findings of Multiple Myeloma: Increased number of plasma cells in the marrow, often >30% of cellularity. (Option A ruled out). Plasma cells may infiltrate the interstitium subtly or completely replace normal elements. marrow aspirate- Multiple myeloma\" data-author=\"KGH\" data-hash=\"9733\" data-license=\"CC BY SA 3.0 \" data-source=\"https://en.wikipedia.org/wiki/ Multiple_myeloma#/media/File:Multiple_myeloma_(1)_MG_stain.jpg\" data-tags=\"April2025\" height=\"252\"",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Hematology-Multiple_Myeloma_Q7_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 8,
      "question": "Match the following conditions with the respective criteria used for their diagnosis . Condition Criteria 1. Plasma Cell Leukemia a) Clonal bone marrow plasma cells ≥ 60% 2. Multiple Myeloma b) Serum monoclonal protein (lgG or IgA) >30 g/L 3. Monoclonal Gammopathy of Undetermined Significance c) Plasma cell count >2000 plasma cells/ µ L 4. Smouldering Multiple Myeloma d) Clonal bone marrow plasma cells<10%",
      "options": {
        "A": "1-c, 2-a, 3-d, 4-b",
        "B": "1-a, 2-d, 3-b, 4-c",
        "C": "1-d, 2-b, 3-c, 4-a",
        "D": "1-b, 2-c, 3-a, 4-d"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) 1-c, 2-a, 3-d, 4-b Explanation: Bone Marrow Evaluation: Precursor lesions of multiple myeloma: Monoclonal gammopathy of undetermined significance (MGUS) Smouldering multiple myeloma (SMM) Diagnostic Criteria for Plasma Cell Leukemia High plasma cell counts >2000 plasma cells/ µ L (c) Diagnostic Criteria for Multiple Myeloma Clonal bone marrow plasma cell percentage ≥ 60% (a) Involved: uninvolved serum-free light chain ratio ≥ 100 Evidence of CRAB or myeloma-defining events in the patient Diagnostic Criteria for Monoclonal Gammopathy of Undetermined Significance (MGUS) Serum monoclonal protein (non-Ig M type) <30 g/L Clonal bone marrow plasma cells <10% (d) Absence of myeloma - defining events or amyloidosis Diagnostic Criteria for Smoldering Multiple Myeloma (SMM) Serum monoclonal protein (lgG or IgA) >30 g/L (b) Clonal bone marrow plasma cells 10-60% Absence of myeloma-defining events or amyloidosis Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page 871,872 https://pmc.ncbi.nlm.nih.gov/articles/PMC6860969/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 9,
      "question": "A 58-year-old male presents with persistent back pain, fatigue, and recurrent minor fractures. Laboratory tests show anemia, elevated serum creatinine, and hypercalcemia. An X-ray of the skull is taken, which is shown below. What is the most likely diagnosis?",
      "options": {
        "A": "Metastasis",
        "B": "Multiple myeloma",
        "C": "Eosinophilic granuloma",
        "D": "Hyperparathyroidism"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Multiple myeloma Explanation: The combination of persistent back pain, fatigue, anemia, elevated serum creatinine, hypercalcemia, and characteristic \"raindrop\" skull appearance on X-ray, which is indicative of osteolytic lesions, strongly suggests Multiple myeloma. Lytic Lesions in Multiple Myeloma: Multiple myeloma typically presents as destructive plasma cell tumors (plasmacytomas) involving the axial skeleton. Commonly affected bones: Vertebral column > Ribs > Skull > Pelvis > Femur > Clavicle > Scapula. Lesions start in the medullary cavity, erode cancellous bone, and progressively destroy the bony cortex. Lesions are common in men > women, with the peak incidence of approximately 55 years of age. Pathologic fractures are common, especially in the vertebral column, but can occur in any affected bone. \"Raindrop skull\" appearance is pathognomonic for multiple myeloma. Radiographic appearance: Multiple punched-out lytic lesions,",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Hematology-Multiple_Myeloma_Q9_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 10,
      "question": "A 58-year-old male presents with fatigue, bone pain, and recurrent infections. Lab tests show elevated β 2-microglobulin and low albumin levels. Which of the following drugs is not part of his initial therapy for transplant-eligible patients?",
      "options": {
        "A": "Bortezomib",
        "B": "Lenalidomide",
        "C": "Cyclophosphamide",
        "D": "Dexamethasone"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Cyclophosphamide Explanation: The patient's symptoms, like fatigue, bone pain, recurrent infections and lab findings of elevated β 2-microglobulin and low albumin levels, suggest a diagnosis of Multiple myeloma. Cyclophosphamide , an alkylating agent, is not part of the induction therapy of transplant-eligible candidates as it causes stem cell loss. Treatment of Multiple Myeloma: Induction Phase: Drugs used: Steroids: Dexamethasone/Prednisolone (Option D) Immunomodulatory agents: Thalidomide/Lenalidomide (Option B) Proteasome inhibitors: Bortezomib/Carfilzomib (Option A) Targeted antibodies: Daratumumab (CD 38 Ab) Autologous Stem Cell Transplantation: Involves removal, storage, and reinfusion of the patient’s own stem cells after high-dose myeloablative therapy. Prognosis of Multiple Myeloma: Durie-Salmon staging system (earlier) International Staging System (ISS): Three-stage system to predict survival based on: β 2-microglobulin Albumin levels Management of Plasma Cell Disorders: Monoclonal Gammopathy of Undetermined Significance (MGUS): No immediate treatment is required. Follow-up: Every 6 months, monitor for progression. Treatment: Initiated only if neuropathy or other symptoms arise. IgM MGUS with neuropathy: Consider plasmapheresis or rituximab. IgG or IgA MGUS with progression: Treat similarly to multiple myeloma. Smoldering Myeloma (High-risk): Lenalidomide and dexamethasone may be considered to delay the progression to symptomatic myeloma. Plasmacytoma: Treated with local radiotherapy (40 Gy is the standard dose).",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 11,
      "question": "A 64-year-old man presents with fever, fatigue, and recurrent infections. On further evaluation, his serum IgM level is 5g/dl. Which of the following is least likely to be associated with this condition?",
      "options": {
        "A": "Peripheral neuropathy",
        "B": "Bone pain",
        "C": "Retinal vessel segmentation",
        "D": "Recurrent infections"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Bone pain Explanation: The clinical scenario suggests the diagnosis of Waldenstorm macroglobulinemia and bone pain is least likely to be associated with WM. Bone pain rarely occurs and is more associated with the infiltration of the bone marrow or skeletal complications of WM rather than with the hyperviscosity effects, which are the main pathology behind WM. Waldenstorm macroglobulinemia (WM) is a malignancy characterized by lymphoplasmacytic cells that secrete IgM, with key features including lymphadenopathy , hepatosplenomegaly , and hyperviscosity syndrome . Clinical features: Weakness. Fatigue. Recurrent infections. (Option D) Visual disturbances due to hyperviscosity ( symptoms of hyperviscosity are the most important). Typically presents with severe sensorimotor peripheral neuropathy. (Option A) It may also exhibit signs resembling chronic lymphocytic leukemia (CLL), myeloma, or lymphocytic lymphoma. Adenopathy and hepatosplenomegaly. Vascular segmentation of retinal vessels (Option C) is caused due to hyperviscosity . Pathogenesis: The disease involves dysregulation of immune signaling pathways, particularly those associated with Toll-like receptors (TLRs) and interleukin receptors, leading to increased cell growth and survival. WM is more common in men and typically presents in individuals around 64 years of age. Investigations: Serum IgM level >3g/dl . Bone marrow shows over 10% infiltration of lymphoplasmacytic cells, often with increased mast cells. Not diagnostic & any level of IgM and bone marrow infiltration can be present. Normocytic normochromic anaemia may be seen. Treatment: Treatment is generally initiated only for symptomatic patients or those with worsening anemia, hyperviscosity, or organomegaly. Plasmapheresis. Drugs like Ibrutinib, bendamustine, cyclophosphamide, and carfilzomib are used, often in combination with rituximab. Fludarabine and cladribine are effective single-agent options. High-dose therapy with autologous stem cell transplantation is an option but is less commonly used due to effective alternative therapies. Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page 876, 877.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    },
    {
      "q_no": 12,
      "question": "Which of the following components does not characterise POEMS syndrome?",
      "options": {
        "A": "Peripheral edema",
        "B": "Skin changes",
        "C": "Endocrine manifestations",
        "D": "Organomegaly"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Peripheral edema Explanation: The POEMS syndrome is not characterized by peripheral edema, even though it is an additional symptom of the disease. Definition: POEMS syndrome is characterized by a combination of polyneuropathy , organomegaly , endocrinopathy , M-protein , and skin changes . P olyneuropathy O rganomegaly (Option D) E ndocrine M anifestations (Option C) S kin changes (Option B) Patients typically experience severe, progressive sensorimotor polyneuropathy linked to sclerotic bone lesions associated with myeloma. Hepatomegaly Lymphadenopathy Splenomegaly Women may experience amenorrhea. Males may have impotence and gynecomastia. Hyperprolactinemia is also seen. Hyperpigmentation Hypertrichosis Skin thickening, Digital clubbing. Associated conditions: Patients may be associated with conditions like: Type 2 diabetes mellitus Hypothyroidism Adrenal insufficiency . Other symptoms: Additional features may include: Peripheral edema Ascites Pleural effusions Fever Thrombocytosis Not all symptoms may be present at diagnosis. Pathogenesis: The exact cause is unclear, but high levels of proinflammatory cytokines like IL-1, IL-6, VEGF, and TNF have been noted. A lower-than-expected level of the inhibitory cytokine TGF- β is also seen. Treatment approaches: Treatment for myeloma often improves other manifestations of POEMS syndrome. Plasma exchange is generally ineffective. Local therapies, such as: Radiotherapy for plasmacytoma may alleviate neuropathic symptoms. Autologous stem cell transplantation is found effective. Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page 877.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Hematology-Multiple Myeloma"
    }
  ]
}
